Manni Mohyuddin (@ManniMD1) / X

Manni Mohyuddin

7,774 posts

Manni Mohyuddin

@ManniMD1

Cancer doctor with interest in myeloma, supportive care, end of life, cost-effective/evidence-based care and med-ed. Views own.

Salt Lake City, UT

Joined June 2020

Pinned
Manni Mohyuddin
@ManniMD1
Jan 30, 2022
For those that just followed me: I tweet about plasma cell disorders. I feel strongly about end-of-life, medical education and calling out what I feel is wrong (such as bad control arms, hype etc) I write educational 🧵occasionally- compiled here👇 bit.ly/32JUGv3 #mmsm
Manni Mohyuddin
@ManniMD1
Oct 5, 2021
So as a junior myeloma faculty, I see a lot of consults for MGUS. Heres a tweetorial on how to interpret light chain values in the setting of kidney disease, as light chains are often checked to look for plasma cell disorders when patients have CKD. 🧵 #mmsm #MedTwitter
Manni Mohyuddin
@ManniMD1
Jun 12, 2023
Just out in @JAMAInternalMed, we highlight a mechanism to detect selection bias/confounding in observational studies by looking at Kaplan Meier curves. If the curves separate implausibly early, the findings are too good to be true! jamanetwork.com/journals/jamai… @VPrasadMDMPH
Manni Mohyuddin
@ManniMD1
Jul 8, 2022
Ever wondered about the staging of myeloma? Why is it so confusing? Why are there three stages (as opposed to 4)? How many staging systems are there? What all contributes to risk? Heres a 🧵 that goes over the past, present and future of myeloma staging. Read on! #mmsm
Manni Mohyuddin
@ManniMD1
May 1, 2024
Ten important observations about myeloma and its precursors that I often discuss with patients and teach to trainees in my clinic. An educational thread 🧵 #mmsm 1/
Manni Mohyuddin
@ManniMD1
Oct 12, 2023
A very common consult that hematologists get is for MGUS in the setting of neuropathy. Are they associated? What diagnosis can explain the association? What workup needs to be ordered? In this thread, we do a deep-dive on this important topic/outline management. #mmsm 🧵 1/
Manni Mohyuddin
@ManniMD1
Feb 23, 2022
I am not a key opinion leader, and I do not take any money from pharma. It is likely my opinion is irrelevant, but I thought I would offer the unfiltered truth about major pharma companies that make #mmsm drugs in a humorous and authentic way. Free consulting in this 🧵
Manni Mohyuddin
@ManniMD1
Dec 11, 2022
When you meet your hematology soulmate for the first time after publishing 12 papers together @AaronGoodman33 #ASH22
Manni Mohyuddin
@ManniMD1
Feb 10, 2023
The first randomized trial of CAR-T in multiple myeloma. nejm.org/doi/full/10.10… Ide-cel versus a choice of five regimens for relapsed multiple myeloma! Lots to learn and process from this trial- so let us get started with this deep-dive 🧵 #mmsm
Manni Mohyuddin
@ManniMD1
Jun 8, 2022
This article broke my heart and reminded me of all the toxicity in academia. I never have condoned any harsh speech against anyone, but I do have reason to believe I am being referred to in this article. I will highlight some themes in this important 🧵
Hematologic Oncology News | Blood Cancers Today
From bloodcancerstoday.com
Manni Mohyuddin
@ManniMD1
Dec 12, 2023
How to treat myeloma after #ASH23 -don’t treat high risk smoldering -do quads for transplant eligible (but no cd38 maintenance afterwards) -don’t do quads or carfilzomib in newly diagnosed frail/older patients -don’t do a salvage auto no matter how good the first auto was
Manni Mohyuddin
@ManniMD1
Nov 9, 2022
I am excited to be on the @ASH_hematology News Daily editorial board, and will be covering/attending the meeting this year. In this 🧵, I will highlight the top 10 myeloma abstracts that most influence my thought and practice from the #ASH22 meeting! #mmsm
Manni Mohyuddin
@ManniMD1
Nov 12, 2022
After ending two weeks on the BMT inpatient service, here is a 🧵 on my favorite BMT CTN trials that I teach to every new fellow/PA/NP/pharmacist/trainee on rounds. I love these trials, and look forward to the ongoing ones! (CAVEAT-trials simplified for purpose of 🧵) #bmtsm
Manni Mohyuddin
@ManniMD1
Mar 28, 2022
Prophylactic anticoagulation and risk of DVT in myeloma- a 🧵 on the evidence, a few case vignettes, and some guidance (based on VERY imperfect evidence). Read on. #mmsm #medtwitter